SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM’S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES
SUZHOU,China, Oct. 27, 2022 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) has recently received a GMP compliance inspection report approved by a Qualified Person ("QP") in the European Union ("EU") in respect of the manufacturing facilities and associated quality systems of the Group's commercial production base for its self-developed HER2-targeted antibody drug conjugate ("ADC") candidate, TAA013. Pursuant...
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
Initial focus on accelerating development of 2seventy's MAGE-A4 program in solid tumors in China SHANGHAI, China and CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, and 2seventy bio (NASDAQ: TSVT), a leading...
Samsung Biologics Reports Third Quarter 2022 Financial Results
Recorded consolidated revenue of KRW 873 billion in Q3'22 Recorded consolidated operating profit of KRW 324.7 billion in Q3'22 Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms INCHEON, South Korea, Oct. 27, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing...
Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The announcement was made at the AusBiotech 2022 national conference,...
Texas Cardiac Arrhythmia Institute physician led international workshop on cardiac arrhythmias
AUSTIN, Texas, Oct. 26, 2022 /PRNewswire/ -- The executive medical director of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently led Venice Arrhythmias 2022, a biennial international workshop on cardiac arrhythmias held in Venice, Italy from October 13 to October 15, 2022. As Venice Arrhythmias president, Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., organized the programming for the...
Waterdrop Opens Its First Community outlet in Shenzhen to Explore the “Insurance + Community” Model
BEIJING, Oct. 26, 2022 /PRNewswire/ -- Waterdrop recently opened its first independent personal insurance agent-based community outlet in Shenzhen, which is the first outlet that cooperates with community healthcare centers on insurance service. Critical to Shenzhen's medical service system, community healthcare centers, rooted in residential communities, aim to create "10-minute medical service circles" and meet people's daily healthcare needs....
Lunit Joins World Economic Forum Global Innovators Community
Lunit invited to join the World Economic Forum's Global Innovators Community, an invitation-only group of the world's most promising start-ups and scale-ups at the forefront of technological and business model innovation In 2020, Lunit was nominated among hundreds of candidates as one of the World Economic Forum's "Technology Pioneers" SEOUL,...
OncoK9®, the Pioneering Blood-Based Early Cancer Detection Test for Dogs, Now Available in Asia Through Asia Veterinary Diagnostics
In the first expansion of access beyond North America, the OncoK9® test from PetDx® is now available in Hong Kong, Singapore, Malaysia, South Korea, and Cambodia at veterinary clinics served by Asia Veterinary Diagnostics. SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- PetDx® – The Liquid Biopsy Company for Pets™ is pleased to announce...
Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication
--ASC10 has two indications: monkeypox and SARS-CoV-2 virus infections. The Investigational New Drug (IND) application of the latter was approved by the U.S. Food and Drug Administration (FDA) in August 2022 and Phase Ib clinical trial in COVID-19 patients is underway in the U.S. --Preclinical studies shows that ASC10 has potent antiviral activities against both monkeypox and SARS-CoV-2...
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given...
